AS01B adjuvant mechanisms and CD4 T cell responses

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200
• Papers screened using: AS01B Adjuvant Focus, CD4 T Cell Response Measurement, Appropriate Study Type, AS01B Data Availability, CD4 T Cell Data Inclusion, CD4 T Cell Response Focus, AS01B Effect Attribution, Full Publication Status
• n = 190 Papers screened out
• n = 10 Papers included for extraction

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses”

The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• AS01B Adjuvant Focus: Does this study investigate AS01B adjuvant specifically (containing MPL and QS-21 in liposomes)?
• CD4 T Cell Response Measurement: Does this study measure CD4 T cell responses as primary or secondary outcomes (including CD4 T cell activation, proliferation, cytokine production, memory formation, or phenotypic characterization)?
• Appropriate Study Type: Is this study either a human clinical trial (Phase I, II, III, or IV) or an animal study using established laboratory models?
• AS01B Data Availability: Does this study include AS01B data (rather than focusing solely on other AS adjuvant systems like AS01E, AS02, AS03, or AS04 without any AS01B data)?
• CD4 T Cell Data Inclusion: Does this study include CD4 T cell data (rather than measuring only antibody responses without any CD4 T cell data)?
• CD4 T Cell Response Focus: Does this study include CD4 T cell response data (rather than focusing exclusively on CD8 T cell or innate immune responses without any CD4 T cell data)?
• AS01B Effect Attribution: Can the AS01B adjuvant effects be separated and attributed specifically to AS01B in this study (rather than being confounded with other interventions)?
• Full Publication Status: Is this a full-text publication (rather than only a conference abstract without full publication)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper.

• Study Context:

Extract key study design information relevant to AS01B adjuvant mechanisms and CD4 T cell responses, including:

• Study population (species, age, health status)

• Antigen used with AS01B

• Study design (randomized, controlled, etc.)

• Sample size for AS01B group

• Dosing schedule and timing of assessments

• AS01B Mechanisms:

Extract all mechanistic data showing how AS01B works at the innate immunity level, including:

• Specific cytokines induced by AS01B (IL-6, IFN-γ, CRP, etc.)

• Signaling pathways activated (IFN-signaling, other pathways)

• Innate immune cell responses

• Timeline of mechanistic responses (peak times, duration)

• Any molecular mechanisms described

• Gene expression changes or mRNA responses

• CD4 Responses:

Extract all CD4 T cell response data specifically for AS01B, including:

• CD4 T cell proliferation or activation markers

• Cytokine production by CD4 cells (IFN-γ, IL-2, IL-5, TNF-α)

• CD4 T cell counts or frequencies

• Functional assays (ELISpot, intracellular staining)

• Persistence/durability of CD4 responses

• Any CD4 subset analysis (Th1, Th2, etc.)

• Statistical measures (means, medians, confidence intervals)

• Mechanism-Response Links:

Extract any evidence directly connecting AS01B mechanisms to CD4 T cell responses, including:

• Correlation analyses between innate responses and CD4 outcomes

• Temporal relationships between mechanistic activation and CD4 responses

• Modeling or regression analyses linking mechanisms to CD4 responses

• Statements about causal relationships

• Dose-response relationships

• Any mechanistic explanations for CD4 responses

• Adjuvant Comparisons:

Extract comparative data between AS01B and other adjuvants for both mechanisms and CD4 responses, including:

• Other adjuvants tested (AS01E, AS02A, AS03, AS04, Alum, etc.)

• Comparative mechanistic profiles (which pathways/cytokines differ)

• Comparative CD4 T cell responses

• Rankings or relative potency comparisons

• Statistical comparisons between adjuvants

• What makes AS01B unique compared to other adjuvants

• Key Findings:

Extract the main conclusions and key findings specifically about AS01B adjuvant mechanisms and CD4 T cell responses, including:

• Primary conclusions about AS01B’s mechanism of action
• Key findings about AS01B’s ability to induce CD4 responses
• Novel insights about AS01B compared to other adjuvants
• Clinical relevance or implications for vaccine development
• Authors’ interpretation of AS01B’s optimal use
• Any limitations or gaps identified regarding AS01B mechanisms

Results

Characteristics of included studies

The included studies span multiple vaccine platforms and species, with three studies using full-text data and seven relying on abstract-only information. Studies evaluated AS01B across diverse antigens including malaria (RTS,S, PfRH5, MSP1(42), LSA1), herpes zoster (gE), hepatitis B (HBsAg), and HIV-1 (gp120/NefTat, F4). Study populations included healthy human adults in six studies, mice in three studies, and rhesus monkeys in one study. Most studies compared AS01B to other adjuvant systems, particularly AS02 variants, AS03, AS04, and aluminum-based adjuvants.

AS01B mechanisms at the innate immunity level

AS01B consistently induced IFN-γ production across multiple studies, with one study providing the most comprehensive mechanistic characterization. Burny et al. demonstrated that AS01B induced transient innate responses including IL-6 and CRP, which peaked at 24 hours post-vaccination and returned to baseline within 1-3 days. Critically, after the second injection, AS01B increased IFN-γ levels and upregulated IFN-γ-inducible protein-10 and IFN-inducible genes. At the molecular level, AS01B activated the IFN-signaling pathway, evidenced by upregulation of STAT1, IRF1, MX1, and CXCL10 at day 31.

Nielsen et al. revealed a distinct mechanistic profile showing AS01B activated pathways associated with Th2 differentiation, including PPAR, FcεRI, and TGF-β pathways, with corresponding cytokines IL-4, IL-5, and IL-13. This suggests AS01B may activate both Th1-associated (IFN-γ) and Th2-associated pathways depending on context. The synergistic combination of MPL and QS-21 in AS01B appeared central to these effects.

CD4 T cell responses induced by AS01B

AS01B consistently induced robust CD4 T cell responses across diverse antigens and species. Kester et al. demonstrated that AS01B elicited a median of 963 CSP-specific CD4+ T cells per 10^6 CD4+ T cells compared to 308 with AS02A, with mean ex vivo IFN-γ ELISPOTs of 212 versus 96 spots/million cells. Multiple studies confirmed high lymphoproliferative capacity and vigorous CD4 T cell activation.

Notably, AS01B demonstrated exceptional durability of CD4 responses. Leroux-Roels et al. (2010) showed CD4+ T-cell responses remained detectable 18 months after the last immunization, while the 2014 study found persistence for at least 3 years after primary vaccination and 6 months after a booster dose. Pichyangkul et al. observed IFN-γ responses lasting at least 24 weeks.

Regarding CD4 subset polarization, studies revealed context-dependent Th1/Th2 skewing. Most studies emphasized strong Th1 responses characterized by high IFN-γ production. However, Nielsen et al. demonstrated that AS01B with protein antigens induced a greater Th2/Tfh2 bias compared to viral vectors, with a higher proportion of Th2 and Tfh2 cells and lower Th1:Th2 cytokine ratios. This Th2 skewing was associated with enhanced humoral immunity.

Comparative adjuvant effects

AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants. In the most comprehensive head-to-head comparison, Burny et al. established a potency ranking of AS01B ≥ AS01E > AS03 > AS04 > Alum for both innate and adaptive responses. Fochesato et al. quantified AS01B’s superiority, showing it induced CD4 T cell responses 5.4-fold greater than AS03, 2.8-fold greater than AS04, and 2.2-fold greater than AS01E (p<0.001 for all comparisons).

Mechanistically, AS01B shared IFN-signaling pathway activation with AS03, but induced higher magnitude innate responses. AS01E, containing half the MPL and QS-21 of AS01B, produced comparable innate profiles but consistently lower CD4 responses. AS02A formulations induced a balanced Th1/Th2 response rather than the strong Th1 bias of AS01B, and showed lower efficacy (32% vs 50%) with fewer CSP-specific CD4+ T cells (median 308 vs 963 per 10^6 CD4+ T cells).

Mechanistic links between AS01B activation and CD4 T cell responses

Burny et al. provided the most direct evidence connecting AS01B’s innate mechanisms to CD4 outcomes through multi-parametric modeling. The study demonstrated associations between adaptive CD4+ T-cell responses and specific innate traits post-dose 2, particularly activation of the IFN-signaling pathway, CRP responses, and IL-6 responses. The temporal relationship showed increased IFN-γ levels after the second injection correlating with enhanced CD4+ T-cell responses. The authors proposed “trained immunity” and CD4+ T-cell regulation as potential mechanisms linking innate responses to sustained CD4+ T-cell responses.

Nielsen et al. revealed that AS01B’s promotion of a Th2 response was mechanistically linked to better B cell help and antibody production. The platform induced higher magnitude antigen-specific cTfh cells, which correlated with humoral immunity markers including IgG concentrations and memory B cell frequencies. RNA-seq data showed higher expression of genes related to Tfh and Th2 cell differentiation in AS01B vaccinees, providing a mechanistic basis for the observed Th2 bias.

The dose-response relationship between AS01B components and CD4 responses was evident in the AS01E comparison. AS01B contains twice the amount of MPL and QS-21 as AS01E, and this correlated with higher CD4 T-cell responses. The synergistic combination of MPL and QS-21 appeared critical, as studies consistently emphasized their combined effect in inducing CD4 responses.

Brando et al. provided cellular-level evidence that CD4+ cells were the main IFN-γ-producing splenocytes in response to AS01B immunization, establishing a direct causal link between AS01B and CD4+ T cell activation. However, blocking anti-CD4+ antibody experiments indicated other cell types also contributed to IFN-γ production, suggesting AS01B activates multiple cellular pathways.

Synthesis

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. In the innate phase, AS01B induces transient inflammatory mediators (IL-6, CRP) peaking at 24 hours, followed by delayed IFN-signaling pathway activation after the second dose (days 31-33). This innate activation then drives robust CD4 T cell responses characterized by high magnitude, extended durability (18+ months), and context-dependent Th1/Th2 polarization.

The Th1/Th2 skewing appears platform-dependent rather than contradictory. Protein/AS01B formulations induced Th2/Tfh2-biased responses with enhanced humoral immunity, while most other contexts showed strong Th1 responses. This likely reflects differential pathway activation: PPAR, FcεRI, and TGF-β pathways were upregulated with protein/AS01B, while IFN-signaling dominated in other formulations. Both patterns ultimately enhanced vaccine immunogenicity through complementary mechanisms—Th1 for cellular immunity and Th2 for antibody production.

AS01B’s superiority over AS02A formulations (efficacy 50% vs 32%; 3.1-fold more CD4 cells) likely stems from its liposomal versus emulsion-based delivery of MPL/QS-21. The dose-response relationship is evident: AS01E with half the MPL/QS-21 induced 2.2-fold lower CD4 responses, despite comparable innate profiles. This suggests AS01B’s enhanced efficacy requires both optimal component dosing and liposomal formulation for maximal CD4 activation.

The mechanistic link between innate and adaptive responses is supported by modeling showing CRP, IL-6, and IFN-signaling pathway activation post-dose 2 predicting CD4+ T-cell outcomes. The delayed IFN-γ increase after the second injection suggests a priming-boosting mechanism where initial innate activation conditions the immune system for enhanced CD4 responses upon rechallenge. This explains AS01B’s exceptional durability—responses persisted 3+ years versus weeks for many adjuvants—likely through establishment of long-lived memory CD4+ T cells promoted by sustained IFN-γ production.